Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Investment analysts at William Blair cut their Q2 2017 earnings estimates for shares of Collegium Pharmaceutical in a report issued on Tuesday. William Blair analyst T. Lugo now expects that the specialty pharmaceutical company will post earnings per share of ($0.76) for the quarter, down from their prior forecast of ($0.74). William Blair also issued estimates for Collegium Pharmaceutical’s Q3 2017 earnings at ($0.74) EPS, Q4 2017 earnings at ($0.71) EPS, FY2017 earnings at ($3.01) EPS, FY2018 earnings at ($2.49) EPS and FY2019 earnings at ($1.32) EPS.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.79) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.98) by $0.19. The business had revenue of $2.17 million during the quarter, compared to analyst estimates of $3.55 million. WARNING: “Q2 2017 EPS Estimates for Collegium Pharmaceutical, Inc. Decreased by William Blair (NASDAQ:COLL)” was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://stocknewstimes.com/2017/08/01/q2-2017-eps-estimates-for-collegium-pharmaceutical-inc-decreased-by-william-blair-nasdaqcoll-updated.html.
Several other equities research analysts have also issued reports on COLL. Jefferies Group LLC set a $24.00 price objective on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Saturday, March 25th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price objective (down previously from $30.00) on shares of Collegium Pharmaceutical in a research report on Wednesday, April 19th. Zacks Investment Research lowered shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Wednesday, May 10th. Janney Montgomery Scott reissued a “buy” rating and issued a $25.00 price objective on shares of Collegium Pharmaceutical in a research report on Monday, June 12th. Finally, ValuEngine raised shares of Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Two equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $22.83.
Collegium Pharmaceutical (NASDAQ COLL) opened at 12.72 on Thursday. Collegium Pharmaceutical has a 1-year low of $7.37 and a 1-year high of $20.55. The firm has a 50 day moving average of $11.57 and a 200 day moving average of $12.38. The firm’s market cap is $374.71 million.
A number of large investors have recently added to or reduced their stakes in COLL. NBW Capital LLC raised its stake in Collegium Pharmaceutical by 1.8% in the first quarter. NBW Capital LLC now owns 62,030 shares of the specialty pharmaceutical company’s stock worth $624,000 after buying an additional 1,114 shares during the last quarter. Credit Suisse AG raised its stake in Collegium Pharmaceutical by 9.4% in the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 1,173 shares during the last quarter. Nationwide Fund Advisors raised its stake in Collegium Pharmaceutical by 16.4% in the first quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock worth $101,000 after buying an additional 1,422 shares during the last quarter. American International Group Inc. raised its stake in Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after buying an additional 2,163 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Collegium Pharmaceutical by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 65,305 shares of the specialty pharmaceutical company’s stock worth $656,000 after buying an additional 3,775 shares during the last quarter. 82.30% of the stock is owned by institutional investors and hedge funds.
In other news, insider Paul Brannelly purchased 10,000 shares of the stock in a transaction that occurred on Friday, May 12th. The stock was acquired at an average cost of $9.18 per share, with a total value of $91,800.00. Following the acquisition, the insider now owns 110,227 shares in the company, valued at $1,011,883.86. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 25.76% of the stock is currently owned by company insiders.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
